Cargando…

Neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the Nrf2/HO-1 pathway

BACKGROUND: Diabetic peripheral neuropathy (DPN) is one of the most common chronic complications of diabetes. Diosgenin is a natural steroidal saponin with a variety of beneficial effects, including antidiabetic effects, and is a raw material for the synthesis of carrier hormones. In our study, we a...

Descripción completa

Detalles Bibliográficos
Autores principales: Leng, Jinhong, Li, Xiaohua, Tian, He, Liu, Chang, Guo, Yining, Zhang, Su, Chu, Yang, Li, Jian, Wang, Ying, Zhang, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184706/
https://www.ncbi.nlm.nih.gov/pubmed/32336289
http://dx.doi.org/10.1186/s12906-020-02930-7
_version_ 1783526636271960064
author Leng, Jinhong
Li, Xiaohua
Tian, He
Liu, Chang
Guo, Yining
Zhang, Su
Chu, Yang
Li, Jian
Wang, Ying
Zhang, Ling
author_facet Leng, Jinhong
Li, Xiaohua
Tian, He
Liu, Chang
Guo, Yining
Zhang, Su
Chu, Yang
Li, Jian
Wang, Ying
Zhang, Ling
author_sort Leng, Jinhong
collection PubMed
description BACKGROUND: Diabetic peripheral neuropathy (DPN) is one of the most common chronic complications of diabetes. Diosgenin is a natural steroidal saponin with a variety of beneficial effects, including antidiabetic effects, and is a raw material for the synthesis of carrier hormones. In our study, we aimed to assess the antioxidant effects of diosgenin in diabetic mice. METHODS: Male C57 mice were fed a high-fat diet for 8 weeks and intraperitoneally injected with streptozotocin (STZ) at a dose of 100 mg/kg for 2 consecutive days. Eligible mice were divided into the normal control group (CON), diabetic group (DM), low-dose diosgenin (50 mg/kg) group (DIO50) and high-dose diosgenin (100 mg/kg) group (DIO100). Treatment was started 6 weeks after the induction of diabetes by STZ and continued for 8 weeks. Blood sugar and body weight were monitored dynamically. The behavioural effects of diosgenin were detected by a hot tail immersion test and paw tactile responses. HE staining was used to evaluate edema and degeneration of the sciatic nerve. The levels of SOD, MDA and GPx were tested according to the instructions of the respective kits. The levels of Nrf2, HO-1 and NQO1 were detected by immunofluorescence and Western blotting. Statistical analysis was performed using SPSS, and P < 0.05 was considered statistically significant. RESULTS: Diosgenin decreased the blood glucose levels and increased the body weight of diabetic mice. There was a significant increase in the tail withdrawal latency of diabetic animals, and mechanical hyperalgesia was significantly alleviated after diosgenin treatment. Histopathological micrographs of HE-stained sciatic nerves showed improvement after diosgenin treatment. Diosgenin attenuated the level of MDA but increased the activities of SOD and GPx. Diosgenin increased the expression of Nrf2, HO-1 and NQO1. CONCLUSIONS: Our results demonstrate that diosgenin can ameliorate behavioural and morphological changes in DPN by reducing oxidative stress. The Nrf2/HO-1 signalling pathway was involved in its neuroprotective effects.
format Online
Article
Text
id pubmed-7184706
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71847062020-04-30 Neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the Nrf2/HO-1 pathway Leng, Jinhong Li, Xiaohua Tian, He Liu, Chang Guo, Yining Zhang, Su Chu, Yang Li, Jian Wang, Ying Zhang, Ling BMC Complement Med Ther Research Article BACKGROUND: Diabetic peripheral neuropathy (DPN) is one of the most common chronic complications of diabetes. Diosgenin is a natural steroidal saponin with a variety of beneficial effects, including antidiabetic effects, and is a raw material for the synthesis of carrier hormones. In our study, we aimed to assess the antioxidant effects of diosgenin in diabetic mice. METHODS: Male C57 mice were fed a high-fat diet for 8 weeks and intraperitoneally injected with streptozotocin (STZ) at a dose of 100 mg/kg for 2 consecutive days. Eligible mice were divided into the normal control group (CON), diabetic group (DM), low-dose diosgenin (50 mg/kg) group (DIO50) and high-dose diosgenin (100 mg/kg) group (DIO100). Treatment was started 6 weeks after the induction of diabetes by STZ and continued for 8 weeks. Blood sugar and body weight were monitored dynamically. The behavioural effects of diosgenin were detected by a hot tail immersion test and paw tactile responses. HE staining was used to evaluate edema and degeneration of the sciatic nerve. The levels of SOD, MDA and GPx were tested according to the instructions of the respective kits. The levels of Nrf2, HO-1 and NQO1 were detected by immunofluorescence and Western blotting. Statistical analysis was performed using SPSS, and P < 0.05 was considered statistically significant. RESULTS: Diosgenin decreased the blood glucose levels and increased the body weight of diabetic mice. There was a significant increase in the tail withdrawal latency of diabetic animals, and mechanical hyperalgesia was significantly alleviated after diosgenin treatment. Histopathological micrographs of HE-stained sciatic nerves showed improvement after diosgenin treatment. Diosgenin attenuated the level of MDA but increased the activities of SOD and GPx. Diosgenin increased the expression of Nrf2, HO-1 and NQO1. CONCLUSIONS: Our results demonstrate that diosgenin can ameliorate behavioural and morphological changes in DPN by reducing oxidative stress. The Nrf2/HO-1 signalling pathway was involved in its neuroprotective effects. BioMed Central 2020-04-26 /pmc/articles/PMC7184706/ /pubmed/32336289 http://dx.doi.org/10.1186/s12906-020-02930-7 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Leng, Jinhong
Li, Xiaohua
Tian, He
Liu, Chang
Guo, Yining
Zhang, Su
Chu, Yang
Li, Jian
Wang, Ying
Zhang, Ling
Neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the Nrf2/HO-1 pathway
title Neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the Nrf2/HO-1 pathway
title_full Neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the Nrf2/HO-1 pathway
title_fullStr Neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the Nrf2/HO-1 pathway
title_full_unstemmed Neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the Nrf2/HO-1 pathway
title_short Neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the Nrf2/HO-1 pathway
title_sort neuroprotective effect of diosgenin in a mouse model of diabetic peripheral neuropathy involves the nrf2/ho-1 pathway
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184706/
https://www.ncbi.nlm.nih.gov/pubmed/32336289
http://dx.doi.org/10.1186/s12906-020-02930-7
work_keys_str_mv AT lengjinhong neuroprotectiveeffectofdiosgenininamousemodelofdiabeticperipheralneuropathyinvolvesthenrf2ho1pathway
AT lixiaohua neuroprotectiveeffectofdiosgenininamousemodelofdiabeticperipheralneuropathyinvolvesthenrf2ho1pathway
AT tianhe neuroprotectiveeffectofdiosgenininamousemodelofdiabeticperipheralneuropathyinvolvesthenrf2ho1pathway
AT liuchang neuroprotectiveeffectofdiosgenininamousemodelofdiabeticperipheralneuropathyinvolvesthenrf2ho1pathway
AT guoyining neuroprotectiveeffectofdiosgenininamousemodelofdiabeticperipheralneuropathyinvolvesthenrf2ho1pathway
AT zhangsu neuroprotectiveeffectofdiosgenininamousemodelofdiabeticperipheralneuropathyinvolvesthenrf2ho1pathway
AT chuyang neuroprotectiveeffectofdiosgenininamousemodelofdiabeticperipheralneuropathyinvolvesthenrf2ho1pathway
AT lijian neuroprotectiveeffectofdiosgenininamousemodelofdiabeticperipheralneuropathyinvolvesthenrf2ho1pathway
AT wangying neuroprotectiveeffectofdiosgenininamousemodelofdiabeticperipheralneuropathyinvolvesthenrf2ho1pathway
AT zhangling neuroprotectiveeffectofdiosgenininamousemodelofdiabeticperipheralneuropathyinvolvesthenrf2ho1pathway